“Working with speech recognition company SoundHound for the technology, White Castle will have an AI voice on its speakers interacting with customers and figuring out what the orders are. The companies promise it will process orders in just over a minute.”
The AI will take your order now.
At Prenuvo, we provide whole body, radiation-free MRI scans in order for our patients to focus on early detection of over 500 cancers and diseases.
The most well-known wiki today is Wikipedia. But software to create personal or organization wikis can harvest collective wisdom.
That was fast.
Less than six months after its public release, it appears that OpenAI has shut down its “AI classifier,” an AI-detection tool that the ChatGPT creator had previously billed as a “classifier to distinguish between text written by a human and text written by AIs from a variety of providers.”
“While it is impossible to reliably detect all AI-written text, we believe good classifiers can inform mitigations for false claims that AI-generated text was written by a human,” reads an OpenAI blog post introducing the tool, published January 31 of this year, “for example, running automated misinformation campaigns, using AI tools for academic dishonesty, and positioning an AI chatbot as a human.”
Another stone left unbranded in Twitter’s disastrous X rebrand: CEO Linda Yaccarino’s former username, which was quickly snagged by a troll.
Chinese researchers have announced in a video that they’ve verified LK-99’s ability to conduct current with zero resistance, but questions still linger.
Migraines are characterized by moderate to severe headache attacks and are commonly considered polygenic disorders. Typically, migraines are treated with triptans like serotonin receptor agonists; however, the mechanisms of triptans are debated upon, with these agents only effective in only about 60% of the population.
A new Scientific Reports study discusses the mechanisms of triptans for the treatment of spontaneous migraine attacks by using transcriptomics and metabolomics.
Glossy white-concrete panels clad this holiday home with a pentagonal plan in Italy, which has been designed by Milan studio JM Architecture.
The dwelling is named Pinwheel after its distinctive shape, which was JM Architecture’s solution for the client’s “only request” – that it offers views of both the nearby Lake Maggiore and surrounding alpine valleys.
“While exploring several design options for a compact house to fit on this small plot, we realised that the building constraints and the client’s requirements resulted in the simple geometry of a pentagon shape,” said JM Architecture founder Jacopo Mascheroni.
A pioneering dental medicine project in Japan is making strides toward clinical trials, with the aim of becoming the world’s first tooth-regrowing treatment, according to the country’s national news site Mainichi.
The upcoming trial will be focused on patients affected by anodontia, a genetic condition characterized by the absence of teeth, or partial anodontia, where people are missing some teeth, as described by the National Organization for Rare Disorders (NORD).
Clinical trials are scheduled to begin next July in Japan. If successful, regulatory approval for the tooth-regrowing medicine is anticipated by 2030, potentially heralding groundbreaking advancements in dentistry.
Antiviral therapies are notoriously difficult to develop, as viruses can quickly mutate to become resistant to drugs, or hide within cells. Researchers at NYU have now developed a new approach to antiviral treatment that ignores the fast-mutating proteins on the surface of viruses and instead targets lipids in the membranes of enveloped viruses, which disrupts their protective layers. In a newly published study the researchers showed how these novel peptoid molecules, inspired by the immune system, could inactivate several viruses, including Zika and chikungunya. The team suggests their approach may not only lead to drugs that can be used against many viruses, but could also help overcome antiviral resistance.
“We found an Achilles heel of many viruses: their bubble-like membranes,” said Kent Kirshenbaum, PhD, professor of chemistry at NYU. “Exploiting this vulnerability and disrupting the membrane is a promising mechanism of action for developing new antivirals.” Kirshenbaum is senior author of the team’s published paper in ACS Infectious Diseases, which is titled “Peptidomimetic Oligomers Targeting Membrane Phosphatidylserine Exhibit Broad Antiviral Activity.”
In their paper the authors concluded, “We provide the first evidence for the engagement of distinct viral envelope lipid constituents, establishing an avenue for specificity that may enable the development of a new family of therapeutics capable of averting the rapid development of resistance.”
